Oh, man, I wish I had been in town this week, Pro. Good job for you and your buddies making OPTR shares available at SWEET prices. To top that Yahoo joined in your "thingy" and this message board is out of order. Has that been since 5/13??? So, this time I hope you covered your fine bottom, along with your cohorts. Just now, I find a sweet end to a sweet week. Oh my. See you around, but probably not here. Have any other monikers? Salud.
Yikes, you are still lurking here, pro! Are you still short? What is your target for going short again, or did you stay short since it didn't reach that $7 price.
I've recharacterized some NOVC shares from an IRA into a ROTH. :)) Thanks to the bashers who have managed to keep the price in check for my taxes.
I could live with that... :) Still, IMO we will first see an offer -- the first step of the dance. Then the analysts will join the discussion, and proinvester will be gone forevermore. IMO, he is now long and will soon re-emerge as "profitter". Or not. Gosh, I miss him.
Pharmaceuticals Inc. (OPTR), the antibiotics maker that’s weighing a sale, drew interest from drugmakers including GlaxoSmithKline Plc (GSK) and Japan’s Astellas Pharma Inc. (4503), said two people familiar with the matter. The shares surged.
The maker of the antibiotic Dificid aims to fetch as much as $1 billion in a possible auction, said the people, who asked not to be named because the process is private. Optimer also attracted interest from Cubist Pharmaceuticals Inc. (CBST) and AstraZeneca Plc, said one of the people.
Buying Optimer would allow the drugmakers to generate more revenue from hospitals, as Dificid, the company’s sole drug on the market, treats a bacterium linked to intestinal infections in hospitalized patients. The drugmaker also may prove attractive to peers that already distribute to medical facilities, because they could use existing distribution channels to reduce costs.
Optimer shares climbed as much as 24 percent following Bloomberg’s report. They advanced to $14.48 at 9:37 a.m. in New York, giving the company a market value of almost $700 million.
Optimer said on Feb. 27 that the board would examine “a full range” of strategic alternatives. The company is working with Centerview Partners LLC and JPMorgan Chase & #$%$ the process.
Former Chairman Michael Chang left Optimer last year after the board found that he failed to identify and manage conflict of interest issues tied to a stock grant. The company also replaced Chief Executive Officer Pedro Lichtinger in February, when Optimer disclosed the board’s strategic review.
Representatives for JPMorgan, Astellas, Glaxo, Cubist and AstraZeneca declined to comment. Optimer spokesman David Walsey didn’t return calls seeking comment.
Hi Ucited. I didn't see any new press release from OPTR, so I expect it was an analyst making his projections and listing those previously suspected to be candidates. I welcome their suggestions, but I would welcome more a bid and competition for buying OPTR.
Hey Pro, I suppose you missed putting the 1 before the 4, but you are still low. Did you get your short cover at $7 like you promised you would? Oops, it never got there. Oh my.
High of $14.48... do they have an offer? Or did the shorts get greedy and bump it up? I'll take the buyout as it is more positive than the shorties.
Thanks for bringing this information back. I don't look at this board often. It's always slow bringing a drug to market, and they want to make it worthwhile -- hence the caution.
These exclusions will give clarity to the results. But you know that, don't you?
Ucite, Thanks for posting Baird's comments. It will take a while, and worth the wait -- especially for that first bid. There are always negociations. I think I'll take a nap. :)
Hmm. Mr. Speculation often becomes a party to negociations, once an initial offer is on board. You've already noted two parties and the price can spike up higher than the offer. It's fun to watch, and I'm voting for a show. Already we have cloggers on this board, when we've never had the pleasure of their company before.
It will be awhile. The interesting event today is the change of CEO. That board meeting must have been ... I can come up with a variety of scenarios, but no point in that. Unless we get a starting bid ... IF there is interest, that $15 will come into play early on.
Oh my, Pro. It can't be helped. Too bad you didn't get your $7 cover. Now this will cut into those profits, but you didn't count on them, did you? Did you? Oh my.
O(Reuters) - Optimer Pharmaceuticals Inc (OPTR.O) said it was exploring a possible sale of the company among a full range of alternatives and that Chairman Henry McKinnell would act as chief executive for the duration of the review process.
Optimer shares were up 11.6 percent at $11.95 in premarket trading.
McKinnell will replace Pedro Lichtinger, who has been at the helm since 2010.